PRTN3 and rheumatoid arthritis: In the Assessing Very Early Rheumatoid arthritis Treatment (AVERT) trial the efficacy and safety of abatacept were studied in ACPA-positive patients with early (active synovitis for ≥8 weeks) RA [32].